AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B. This preference might be explained by B4e8׳s extensive interaction with Arg315, which occurs at the center of most subtype B V3 sequences but is replaced by Gln in subtype C. The extent to which B4e8׳s ability to neutralize subtype C strains is hindered by Gln315 and/or other factors, e.g. epitope masking, is unclear. We confirmed here that an Arg315-to-Gln substitution in a subtype B virus abrogates B4e8 neutralizing activity. Conversely, B4e8-resistant subtype C viruses were rendered sensitive upon Gln 315-to-Arg substitution. V2 region swapping between B4e8-sensitive and- resistant subtype C strains revealed a role for V2 in limiting B4e...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The external subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env),...
Author Summary Most HIV-1 infected individuals develop neutralizing antibodies against their own vir...
AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
AbstractThe V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus se...
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine ...
AbstractThe V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet ...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
AbstractOne approach to the development of an HIV vaccine is to design a protein template which can ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The external subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env),...
Author Summary Most HIV-1 infected individuals develop neutralizing antibodies against their own vir...
AbstractAntibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B...
The limited neutralizing activity of V3 antibodies is typically attributed to V3 masking. While rela...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
AbstractThe V3 loop of HIV-1 gp120 is considered occluded on many primary viruses. However, virus se...
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine ...
AbstractThe V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet ...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infectio...
The early autologous neutralizing antibody response in human immunodeficiency virus type 1 (HIV-1) s...
AbstractOne approach to the development of an HIV vaccine is to design a protein template which can ...
Background: Broadly neutralizing antibodies (bnAbs) directed against the mannose-patch on the HIV en...
International audienceBroadly neutralizing antibodies (bnAbs) directed against the mannose-patch on ...
Human Immunodeficiency Virus (HIV-1) is an epidemic that affects over 34 million people worldwide. A...
The external subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env),...
Author Summary Most HIV-1 infected individuals develop neutralizing antibodies against their own vir...